Our mission is to develop and make globally available the first therapy targeting a root cause of preeclampsia.
Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.
Learn About Our WorkMeet Our Team
Read our latest news
January 17, 2024
Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia
August 28, 2023
Comanche Biopharma Named by Fierce Biotech as a “Fierce 15” Biotech Company of 2023
Learn More
Contact Us
50 Beharrell St, Unit B
Concord, MA 01742